GRAIL Investor Securities Fraud Class Action
GRAIL · GRAIL common stock and the Galleri liquid biopsy cancer-detection test · Ongoing Litigation
About this case
Investors allege that GRAIL and certain defendants failed to disclose limitations in the design and execution of the NHS-Galleri trial and withheld information about potentially adverse trends, causing losses after GRAIL disclosed that the trial had not met its primary endpoint. The securities class action is ongoing, and investors had until August 4, 2026, to seek appointment as lead plaintiff.
Case overview
- Defendant company
- GRAIL
- Product or service
- GRAIL common stock and the Galleri liquid biopsy cancer-detection test
- Case status
- Ongoing Litigation
- Lawsuit type
- Securities
- Reported harm
- Misrepresentation
Important dates
- Lead Plaintiff Application
Participation information
Lead Plaintiff Application
Investors who purchased or acquired GRAIL common stock from May 13, 2025 through February 19, 2026 were described as potentially eligible to seek appointment as lead plaintiff.
Seek appointment as a lead plaintiff representative by August 4, 2026. The article directs interested investors to contact Berger Montague, but does not provide a direct application URL.
- Type
- Lead Plaintiff
- Status
- Deadline passed
Sources
- GRAIL Investor Securities Fraud Class Action
Barchart.com ·